Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer.

Adamo B, Rita Ricciardi GR, Ieni A, Franchina T, Fazzari C, Sanò MV, Angelico G, Michele C, Tuccari G, Adamo V.

Oncotarget. 2017 Aug 16;8(44):76974-76986. doi: 10.18632/oncotarget.20293. eCollection 2017 Sep 29.

2.

Basal-like breast cancer: molecular profiles, clinical features and survival outcomes.

Milioli HH, Tishchenko I, Riveros C, Berretta R, Moscato P.

BMC Med Genomics. 2017 Mar 28;10(1):19. doi: 10.1186/s12920-017-0250-9.

3.

Identification of Copy Number Aberrations in Breast Cancer Subtypes Using Persistence Topology.

Arsuaga J, Borrman T, Cavalcante R, Gonzalez G, Park C.

Microarrays (Basel). 2015 Aug 12;4(3):339-69. doi: 10.3390/microarrays4030339.

4.

Claudin 1 in Breast Cancer: New Insights.

Zhou B, Moodie A, Blanchard AA, Leygue E, Myal Y.

J Clin Med. 2015 Nov 27;4(12):1960-76. doi: 10.3390/jcm4121952. Review.

5.

Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.

Perez EA, Ballman KV, Tenner KS, Thompson EA, Badve SS, Bailey H, Baehner FL.

JAMA Oncol. 2016 Jan;2(1):56-64. doi: 10.1001/jamaoncol.2015.3239.

6.

Histological Analysis of γδ T Lymphocytes Infiltrating Human Triple-Negative Breast Carcinomas.

Hidalgo JV, Bronsert P, Orlowska-Volk M, Díaz LB, Stickeler E, Werner M, Schmitt-Graeff A, Kayser G, Malkovsky M, Fisch P.

Front Immunol. 2014 Dec 10;5:632. doi: 10.3389/fimmu.2014.00632. eCollection 2014.

7.

Clinicopathologic characteristics of typical medullary breast carcinoma: a retrospective study of 117 cases.

Chu Z, Lin H, Liang X, Huang R, Zhan Q, Jiang J, Zhou X.

PLoS One. 2014 Nov 6;9(11):e111493. doi: 10.1371/journal.pone.0111493. eCollection 2014.

8.

Integrative genomic and transcriptomic characterization of papillary carcinomas of the breast.

Piscuoglio S, Ng CK, Martelotto LG, Eberle CA, Cowell CF, Natrajan R, Bidard FC, De Mattos-Arruda L, Wilkerson PM, Mariani O, Vincent-Salomon A, Weigelt B, Reis-Filho JS.

Mol Oncol. 2014 Dec;8(8):1588-602. doi: 10.1016/j.molonc.2014.06.011. Epub 2014 Jun 26.

9.

Rare breast cancer subtypes: histological, molecular, and clinical peculiarities.

Dieci MV, Orvieto E, Dominici M, Conte P, Guarneri V.

Oncologist. 2014 Aug;19(8):805-13. doi: 10.1634/theoncologist.2014-0108. Epub 2014 Jun 26.

10.

Clinicopathological features and prognosis of triple negative breast cancer in Kuwait: A comparative/perspective analysis.

Fayaz MS, El-Sherify MS, El-Basmy A, Zlouf SA, Nazmy N, George T, Samir S, Attia G, Eissa H.

Rep Pract Oncol Radiother. 2013 Sep 26;19(3):173-81. doi: 10.1016/j.rpor.2013.08.007. eCollection 2014 May.

11.

Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer.

Maksimenko J, Irmejs A, Nakazawa-Miklasevica M, Melbarde-Gorkusa I, Trofimovics G, Gardovskis J, Miklasevics E.

Oncol Lett. 2014 Jan;7(1):278-284. Epub 2013 Nov 14.

12.

Prognostic value of PLAGL1-specific CpG site methylation in soft-tissue sarcomas.

Peille AL, Brouste V, Kauffmann A, Lagarde P, Le Morvan V, Coindre JM, Chibon F, Bresson-Bepoldin L.

PLoS One. 2013 Nov 15;8(11):e80741. doi: 10.1371/journal.pone.0080741. eCollection 2013.

13.

Genomic insights into triple-negative and HER2-positive breast cancers using isogenic model systems.

Mudvari P, Ohshiro K, Nair V, Horvath A, Kumar R.

PLoS One. 2013 Sep 23;8(9):e74993. doi: 10.1371/journal.pone.0074993. eCollection 2013.

14.

TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.

Maire V, Baldeyron C, Richardson M, Tesson B, Vincent-Salomon A, Gravier E, Marty-Prouvost B, De Koning L, Rigaill G, Dumont A, Gentien D, Barillot E, Roman-Roman S, Depil S, Cruzalegui F, Pierré A, Tucker GC, Dubois T.

PLoS One. 2013 May 20;8(5):e63712. doi: 10.1371/journal.pone.0063712. Print 2013.

15.

Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials.

Huober J, Gelber S, Goldhirsch A, Coates AS, Viale G, Öhlschlegel C, Price KN, Gelber RD, Regan MM, Thürlimann B.

Ann Oncol. 2012 Nov;23(11):2843-51. doi: 10.1093/annonc/mds105. Epub 2012 Jun 14.

16.

A gene signature for predicting outcome in patients with basal-like breast cancer.

Hallett RM, Dvorkin-Gheva A, Bane A, Hassell JA.

Sci Rep. 2012;2:227. doi: 10.1038/srep00227. Epub 2012 Jan 17. No abstract available.

17.

Immunophenotypic and genomic characterization of papillary carcinomas of the breast.

Duprez R, Wilkerson PM, Lacroix-Triki M, Lambros MB, MacKay A, A'Hern R, Gauthier A, Pawar V, Colombo PE, Daley F, Natrajan R, Ward E, MacGrogan G, Arbion F, Michenet P, Weigelt B, Vincent-Salomon A, Reis-Filho JS.

J Pathol. 2012 Feb;226(3):427-441. doi: 10.1002/path.3032. Epub 2011 Dec 9.

18.

Management options in triple-negative breast cancer.

Minami CA, Chung DU, Chang HR.

Breast Cancer (Auckl). 2011;5:175-99. doi: 10.4137/BCBCR.S6562. Epub 2011 Jul 27.

19.

Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer.

Thompson PA, Brewster AM, Kim-Anh D, Baladandayuthapani V, Broom BM, Edgerton ME, Hahn KM, Murray JL, Sahin A, Tsavachidis S, Wang Y, Zhang L, Hortobagyi GN, Mills GB, Bondy ML.

PLoS One. 2011;6(8):e23543. doi: 10.1371/journal.pone.0023543. Epub 2011 Aug 12.

20.

Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: retrospective immunohistochemical study.

Matković B, Juretić A, Spagnoli GC, Separović V, Gamulin M, Separović R, Sarić N, Basić-Koretić M, Novosel I, Kruslin B.

Croat Med J. 2011 Apr 15;52(2):171-7.

Supplemental Content

Support Center